TARIS CLOSES $18.3 MILLION SERIES B FINANCING -- Third Rock Ventures Leads Round -Lexington, MA – April 13 , 2011 – TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, ta - Flybridge Capital Partners - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2011-04-13 07:09:59 Lemelson–MIT Prize Biotechnology Robert S. Langer Taris Flybridge Capital Partners Interstitial cystitis Cystitis Overactive bladder Bladder cancer Medicine Health Urology		TARIS CLOSES $18.3 MILLION SERIES B FINANCING -- Third Rock Ventures Leads Round -Lexington, MA – April 13 , 2011 – TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, ta Add to Reading List Source URL: www.tarisbiomedical.com Download Document from Source Website File Size: 467,17 KB Share Document on Facebook

	TARIS LAB Battle Field LAB An advanced simulation lab • Provides virtual platform to analyze and DocID: 1f1fT - View Document
	Dit artikel van Boom Lemma Tijdschriften is gemaakt voor IedereenARTIKELEN Burnout: de stand van zaken Toon Taris, Irene Houtman & Wilmar Schaufeli* DocID: 1bmlB - View Document
	TARIS CLOSES $18.3 MILLION SERIES B FINANCING -- Third Rock Ventures Leads Round -Lexington, MA – April 13 , 2011 – TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, ta DocID: 1adLw - View Document
	Microsoft Word - TARIS CowenPresentation DocID: 1a2vW - View Document
	TARIS® Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate Lexington, MA – April 2nd, 2013 – TARIS Biomedical®, a specialty pharmaceutical company developing innovative, DocID: 19L9P - View Document